Generate Biomedicines, Inc.

XNASHealth care

Last traded price · USD

$14.47

+2.17%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:40 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $14.16
Volume: 25
Day's high: —
Day's low: —

In brief

Generate Biomedicines, Inc. is a health care company listed on Nasdaq, valued at about $1.86B.
Its shares closed at $14.16 on 4 Nov 2026.
From India you can buy GENB in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Generate Biomedicines, Inc. (GENB) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole GENB share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade GENB options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

8.0 days to cover short interest
8.9M shares were sold short at the 15 Oct 2026 settlement; covering them would take 8.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Behind SPY and its sector fund XLV over 3 months
1 month: +2.6% (SPY −1.6%, XLV +13.5%). 3 months: −2.3% (SPY −0.4%, XLV +15.5%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GENB, SPY and XLV · as of 4 Nov 2026
Below its 50-day average
The 4 Nov 2026 close of $14.16 was 3.9% below its 50-day average ($14.74).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+2.6%

6 months−7.5%

1 year—

5 years—

Newswire

About

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Website

Notable moves

October 28, 2026
+16.43%
August 26, 2026
−20.80%
May 18, 2026
−18.72%

Generate Biomedicines, Inc.

XNASHealth care

Last traded price · USD

$14.47

+2.17%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:40 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $14.16
Volume: 25
Day's high: —
Day's low: —

In brief

Generate Biomedicines, Inc. is a health care company listed on Nasdaq, valued at about $1.86B.
Its shares closed at $14.16 on 4 Nov 2026.
From India you can buy GENB in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Generate Biomedicines, Inc. (GENB) shares from India?

Do I need the price of a whole GENB share to invest?

How much can I invest in US stocks in a year?

Can I trade GENB options or futures?

Insights

Quotes run fifteen minutes behind.

8.0 days to cover short interest
8.9M shares were sold short at the 15 Oct 2026 settlement; covering them would take 8.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Behind SPY and its sector fund XLV over 3 months
1 month: +2.6% (SPY −1.6%, XLV +13.5%). 3 months: −2.3% (SPY −0.4%, XLV +15.5%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GENB, SPY and XLV · as of 4 Nov 2026
Below its 50-day average
The 4 Nov 2026 close of $14.16 was 3.9% below its 50-day average ($14.74).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+2.6%

6 months−7.5%

1 year—

5 years—

Newswire

About

Website

Notable moves

October 28, 2026
+16.43%
August 26, 2026
−20.80%
May 18, 2026
−18.72%

Generate Biomedicines, Inc.

Generate Biomedicines, Inc. in brief

8.0 days to cover short interest

Behind SPY and its sector fund XLV over 3 months

Below its 50-day average

Generate Biomedicines, Inc.

Generate Biomedicines, Inc. in brief

8.0 days to cover short interest

Behind SPY and its sector fund XLV over 3 months

Below its 50-day average